bioMérieux Industry Announces AOAC Approval for the VIDAS® Capylobacter (CAM) Assay and Campy Food Agar Enumeration Method

bioMérieux, a world leader in the field of in vitro diagnostics, today announced AOAC Research institute Performance Tested MethodSM (PTM) approvals for the automated VIDAS® Campylobacter (CAM) detection assay and the Campy Food Agar (CFA) enumeration and detection methods.

Campylobacter is one of the most common causes of diarrheal illness in the United States. Active surveillance through FoodNet indicates that about 13 cases are diagnosed each year for each 100,000 persons in the population¹. Campylobacteriosis is estimated to affect over 2.4 million persons every year, or 0.8% of the population¹. Most cases of campylobacteriosis are associated with eating raw or undercooked poultry meat or from cross-contamination of other foods by these items in addition to unpasteurized milk or contaminated water.

The VIDAS® CAM (PTM # 051201) and CFA (PTM # 071201) methods have been validated and certified as effective methods for the detection of chicken carcass rinsate and turkey carcass sampled sponges when compared to USDA/FSIS MLG 41.00 reference method; and as effective detection methods for fresh pork, raw chicken breast and processed chicken nuggets when compared to ISO 10272-1 and 2:2006 reference methods. CFA was also approved for the enumeration of carcass rinsate, turkey carcass sampled sponges, raw pork, raw chicken breast and processed chicken nuggets when compared to the USDA/FSIS MLG 41.00 reference method and ISO 10272-1 and 2:2006 reference methods, respectively.

"Food laboratories today are striving to improve productivity and shorten their time-to-results," said Jean-Marc Durano, Corporate Vice President, Industrial Microbiology Unit. "Providing a fully integrated and AOAC validated solution for Campylobacter is a significant milestone in minimizing foodborne pathogens in the meat and prepared foods industry".

For more information on VIDAS (CAM) and Campy Food Agar along with other bioMérieux Industry technologies, please visit www.biomerieux-industry.com.

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 40 subsidiaries and a large network of distributors. In 2011, revenues reached €1.427 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Additional information can be found at www.biomerieux.com.

Media Contacts

bioMérieux
Koren Wolman-Tardy
Tel.: + 33 4 78 87 20 08
media@biomerieux.com

Pascal Cruveiller
Tel.: + 33 4 78 87 50 19
indusmicro@biomerieux.com

Image Sept
Laurence Heilbronn
Tel.: + 33 1 53 70 74 64
lheilbronn@image7.fr

¹ United States Department of Agriculture, Food Safety Inspection Services

Download the Complete Press Release: